Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1Breast 1

Conditions

Multiple Endocrine Neoplasia Type 1 1Essential Hypertension 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × candesartan × Clear all
NCT04429633 2020-06-12

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Samsung Medical Center

Phase NA Unknown
136 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡